<DOC>
	<DOC>NCT01944033</DOC>
	<brief_summary>The effectiveness of β2-agonists in the treatment of exacerbations of COPD is already established. The purpose of this study is to compare the effectiveness of the β2-agonists alone in nebulization with the association β2-agonists + Ipratropium bromide in the treatment of an acute exacerbation of COPD consulting the emergency departement based on the clinical and the aarterial blood gas.</brief_summary>
	<brief_title>β2-agonist Versus Ipratropium Bromide Associated With β2-agonists in Chronic Obstructive Pulmonary Disease Exacerbation</brief_title>
	<detailed_description>It is a prospective study and randomized practiced in patients consulting the emergency departement for an acute exacerbation of COPD. The patients were divided in two groups: Group AB; received β2-agonists + Ipratropium bromide in nebulization and Group B received β2-agonists alone in nebulization)</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Terbutaline</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>have known or suspected COPD based on pulmonary function test, arterial blood gas, clinical history, physical examination, and chest radiograph Age over 18 years old. COPD Exacerbation: FR&gt;25c/min PaCO2&gt;6Kpa PH&lt;7,35 SaO2&lt;90% GCS ≤ 12 hypersensitivity to anticholinergic severe acidosis lack of patient cooperation serious heart arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>β2-agonist</keyword>
	<keyword>Ipratropium Bromide</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease Exacerbation</keyword>
	<keyword>Emergency departement</keyword>
</DOC>